Jul. 13 at 4:54 AM
$CING — my thesis at
$4.90
Holding 2,101 shares, avg
$5.99. Down but not out here’s why I’m still in:
The June CRL was CMC-only — FDA flagged manufacturing/formulation details, not clinical safety or efficacy for CTx-1301. That’s a fixable problem, not a dead drug.
Cash position is solid:
$25.9M as of Q1 26, runway into 2027 after the
$12M raise. No dilution panic needed while they work the resubmission.
Falcon Creek Capital led that raise at
$5.04/share (basically where we’re trading now) and holds board seats. Smart money bought in near current levels.
Added to the Russell 3000E in the June reconstitution + locked in a fully-owned US patent on CTx-1301 through 2042.
Catalyst: FDA resubmission/decision expected Q1–Q2 2027. Next print is Aug 18 earnings.
This is a binary, micro-cap biotech bet — not for everyone. But the setup (CMC-only issue + funded runway + institutional buy-in near these prices) is why I’m holding through the resubmission.
NFA, DYOR.
